Fibrocystin/polyductin (FPC): new functional insights into ARPKD pathogenesis revealed by informatics, comparative genomics, and model systems

Document Type

Journal Article

Publication Date

1-28-2026

Journal

Pediatric nephrology (Berlin, Germany)

DOI

10.1007/s00467-025-07129-x

Keywords

Autosomal recessive polycystic kidney disease (ARPKD); Cilia-dependent cyst activation (CDCA) signal; Experimental models; Fibrocystin/polyductin (FPC); Genotype-phenotype

Abstract

Autosomal recessive polycystic kidney disease (ARPKD) is the prototype of the hepato-renal fibrocystic diseases, a subset of the broader ciliopathy disorders. As a severe form of PKD, ARPKD typically manifests in utero with 21% perinatal mortality and progressive loss of kidney function in most post-natal survivors. Congenital hepatic fibrosis is an invariant feature of ARPKD. PKHD1-encoded fibrocystin/polyductin (FPC) is a large 4074 amino acid glycoprotein that likely functions as a receptor molecule and appears to play a key role in maintaining differentiated renal tubular epithelium. The molecular mechanisms by which defects in FPC contribute to ARPKD pathogenesis are just beginning to be elucidated. FPC is a novel protein that likely evolved as vertebrates transitioned from aquatic to semi-terrestrial ecosystems. Full-length human FPC shares a phylogenetically conserved, multi-motif N-terminal region with its ancestral homolog, PKHD1L1, and contains a single-pass transmembrane domain and a novel C-terminal tail that harbors a ciliary targeting motif as well as mitochondrial and nuclear localization sequences. This review synthesizes the full range of recent experimental data about PKHD1/FPC to provide a current functional perspective about this complex protein. We also discuss the clinical relevance of these emerging functional insights for both kidney health and ARPKD pathogenesis.

Department

Pediatrics

Link to Full Text

Share

COinS